DK1677827T3 - Kombinationer til HCV-behandling - Google Patents

Kombinationer til HCV-behandling

Info

Publication number
DK1677827T3
DK1677827T3 DK04810032T DK04810032T DK1677827T3 DK 1677827 T3 DK1677827 T3 DK 1677827T3 DK 04810032 T DK04810032 T DK 04810032T DK 04810032 T DK04810032 T DK 04810032T DK 1677827 T3 DK1677827 T3 DK 1677827T3
Authority
DK
Denmark
Prior art keywords
hepatitis
relates
combinations
virus
combination
Prior art date
Application number
DK04810032T
Other languages
English (en)
Inventor
Roger D Tung
Gurudatt Chandorkar
Robert B Perni
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of DK1677827T3 publication Critical patent/DK1677827T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK04810032T 2003-10-27 2004-10-27 Kombinationer til HCV-behandling DK1677827T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51485303P 2003-10-27 2003-10-27
PCT/US2004/035549 WO2005042020A2 (en) 2003-10-27 2004-10-27 Combinations for hcv treatment

Publications (1)

Publication Number Publication Date
DK1677827T3 true DK1677827T3 (da) 2009-03-30

Family

ID=34549356

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04810032T DK1677827T3 (da) 2003-10-27 2004-10-27 Kombinationer til HCV-behandling

Country Status (22)

Country Link
US (3) US20060003942A1 (da)
EP (1) EP1677827B1 (da)
JP (1) JP2007509950A (da)
KR (1) KR20060120162A (da)
CN (1) CN1893978A (da)
AT (1) ATE416789T1 (da)
AU (1) AU2004285503A1 (da)
BR (1) BRPI0415935A (da)
CA (1) CA2543696A1 (da)
CY (1) CY1110176T1 (da)
DE (1) DE602004018363D1 (da)
DK (1) DK1677827T3 (da)
ES (1) ES2319775T3 (da)
IL (1) IL175211A0 (da)
MX (1) MXPA06004723A (da)
NO (1) NO20062428L (da)
PL (1) PL1677827T3 (da)
PT (1) PT1677827E (da)
RU (1) RU2006118359A (da)
SI (1) SI1677827T1 (da)
WO (1) WO2005042020A2 (da)
ZA (1) ZA200603863B (da)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2314598A1 (en) 1996-10-18 2011-04-27 Vertex Pharmaceuticals Incorporated Inhibitors of Hepatitis C virus NS3 serine protease
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
PE20050374A1 (es) 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
TWI389688B (zh) * 2004-06-08 2013-03-21 Vertex Pharma Vx-950之形態與調配物及其製備方法與用途
WO2006130553A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors
WO2007016589A2 (en) * 2005-08-02 2007-02-08 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP2340836A1 (en) 2006-02-27 2011-07-06 Vertex Pharmceuticals Incorporated Co-crystals comprising VX-950 and their pharmaceutical compositions
MX2008011429A (es) * 2006-03-06 2008-09-18 Abbott Lab Composiciones y metodos de uso de ritonavir para tratar hcv.
BRPI0709567A2 (pt) 2006-03-16 2011-07-12 Vertex Pharma inibidores deuterados de protease de hepatite c
JP2009530415A (ja) * 2006-03-20 2009-08-27 バーテックス ファーマシューティカルズ インコーポレイテッド 医薬組成物
US20070287664A1 (en) * 2006-03-23 2007-12-13 Schering Corporation Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto
MX2008013119A (es) 2006-04-11 2008-10-21 Novartis Ag Inhibidores de hcv/vih y sus usos.
WO2007149382A2 (en) * 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in treating hepatitis
KR101636221B1 (ko) 2006-07-07 2016-07-04 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학 특성의 모듈레이터
US20080181948A1 (en) * 2006-11-15 2008-07-31 Abbott Laboratories Solid pharmaceutical dosage formulations
GEP20125645B (en) * 2007-02-27 2012-09-25 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
AU2008219704A1 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8088770B2 (en) * 2007-07-06 2012-01-03 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CN101835774B (zh) * 2007-08-30 2014-09-17 弗特克斯药品有限公司 共晶体和包含该共晶体的药物组合物
US20090082366A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telaprevir
CN104016970A (zh) 2007-10-10 2014-09-03 诺华股份有限公司 螺环吡咯烷类与其对抗hcv和hiv感染的应用
CN101959506A (zh) * 2008-02-28 2011-01-26 雅培制药有限公司 片剂和其制备方法
JP2012513409A (ja) * 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
CN102245604A (zh) 2008-12-23 2011-11-16 雅培制药有限公司 抗病毒化合物
US8314135B2 (en) * 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
WO2010091413A1 (en) * 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8242156B2 (en) * 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US9339531B2 (en) 2009-02-26 2016-05-17 The Johns Hopkins University Recognition of CYP2E1 epitopes
US8101643B2 (en) * 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
RU2541571C2 (ru) * 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
MX351185B (es) * 2009-04-25 2017-10-04 Hoffmann La Roche Procedimientos para mejorar la farmocinetica.
TWI469780B (zh) * 2009-06-11 2015-01-21 Abbvie Bahamas Ltd 抗病毒化合物
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2010148006A1 (en) * 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011031904A1 (en) * 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8822700B2 (en) * 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) * 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) * 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) * 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8653070B2 (en) * 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
KR20120107529A (ko) 2010-01-25 2012-10-02 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스 억제제
US8178531B2 (en) * 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
US8623814B2 (en) * 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
AU2010347272A1 (en) * 2010-03-04 2012-09-20 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as inhibitors of HCV replication
EP2552933A1 (en) 2010-03-31 2013-02-06 Gilead Pharmasset LLC Purine nucleoside phosphoramidate
US9127021B2 (en) 2010-04-09 2015-09-08 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011153396A1 (en) 2010-06-04 2011-12-08 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
EP2603080A4 (en) 2010-08-12 2014-01-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
BR112013008510A2 (pt) 2010-10-08 2016-07-05 Novartis Ag vitamina e formulações de inibidores de sulfamida ns3
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2012158861A2 (en) 2011-05-18 2012-11-22 Enanta Pharmaceuticals, Inc. Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
RU2013155713A (ru) 2011-07-06 2015-08-20 Профибрикс Бв Составы для лечения ран
DE202012013074U1 (de) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Zusammensetzungen zur Behandlung von HCV
EP2766365A1 (en) * 2011-10-10 2014-08-20 F.Hoffmann-La Roche Ag Antiviral compounds
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
GB2506085A (en) 2011-10-21 2014-03-19 Abbvie Inc Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
RS62030B1 (sr) * 2012-05-18 2021-07-30 Replicor Inc Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci
WO2014004674A2 (en) * 2012-06-27 2014-01-03 Abbvie Inc. Methods for treating hcv
SI2950786T1 (sl) 2013-01-31 2020-03-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
AU2016288699B2 (en) 2015-06-30 2020-11-26 Eiger Group International, Inc. Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
KR20220035365A (ko) * 2019-07-18 2022-03-22 엔요 파마 인터페론의 부작용을 감소시키는 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
BR0210357A (pt) * 2001-06-11 2004-06-29 Shire Biochem Inc Composto e métodos para o tratamento ou a prevenção de infecções pelo flavivìrus
CN1852920B (zh) * 2003-07-18 2010-12-15 沃泰克斯药物股份有限公司 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂
PE20050374A1 (es) * 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
US7365092B2 (en) * 2003-10-10 2008-04-29 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
NZ546663A (en) * 2003-10-10 2010-01-29 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c

Also Published As

Publication number Publication date
ES2319775T3 (es) 2009-05-12
WO2005042020A2 (en) 2005-05-12
US20120114604A1 (en) 2012-05-10
JP2007509950A (ja) 2007-04-19
KR20060120162A (ko) 2006-11-24
PT1677827E (pt) 2009-03-13
IL175211A0 (en) 2006-09-05
BRPI0415935A (pt) 2007-01-02
SI1677827T1 (sl) 2009-06-30
CY1110176T1 (el) 2015-01-14
ATE416789T1 (de) 2008-12-15
NO20062428L (no) 2006-05-29
PL1677827T3 (pl) 2009-06-30
ZA200603863B (en) 2007-11-28
AU2004285503A1 (en) 2005-05-12
WO2005042020A3 (en) 2005-06-23
DE602004018363D1 (de) 2009-01-22
CA2543696A1 (en) 2005-05-12
CN1893978A (zh) 2007-01-10
RU2006118359A (ru) 2007-12-10
EP1677827A2 (en) 2006-07-12
US20060003942A1 (en) 2006-01-05
MXPA06004723A (es) 2006-07-05
US20100015090A1 (en) 2010-01-21
EP1677827B1 (en) 2008-12-10

Similar Documents

Publication Publication Date Title
DK1677827T3 (da) Kombinationer til HCV-behandling
MY148123A (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
SG159385A1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
PT1268519E (pt) Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
MX2009009176A (es) Inhibidores de serina-proteasas.
SG155967A1 (en) Hcv ns3-ns4a protease inhibition
PL1987038T3 (pl) Inhibitory HCV NS5B
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
TNSN08033A1 (en) Hcv ns3 protease inhibitors
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
HK1101402A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
UA90909C2 (en) Hcv ns3 protease inhibitors